12-May-2025 3:05 PM CST - Business Wire Immunome Reports First Quarter 2025 Financial Results and Provides Business Update Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update. Immunome continued to build momentum in the first quarter of 2025, said Clay B. Siegall, Ph.D., President and Chief Executive Officer. We remain on track to share topline data for the RINGSIDE trial of varegacestat in the s
4-Apr-2025 7:00 AM CST - Business Wire Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the companys website at ww
19-Mar-2025 3:05 PM CST - Business Wire Immunome Reports Full Year 2024 Financial Results and Provides Business Update Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update. Immunomes efficient execution in 2024 laid the foundation for a productive 2025, said Clay B. Siegall, Ph.D., President and Chief Executive Officer. We are pleased with the progress of our pipeline and, with multiple
25-Feb-2025 7:00 AM CST - Business Wire Immunome to Present at Upcoming March Conferences Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences in March 2025: TD Cowen 45th Annual Health Care Conference Conference Dates: March 3-5, 2025 Presentation Date/Time: March 4, 2025, 1:10 p.m. ET Leerink Partners Global Healthcare Conference 2025 Conference Dates: March 10-12, 2025 Presentation Date/
13-Jan-2025 7:00 AM CST - Business Wire Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 9:45 a.m. PT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the companys website at www.
27-Nov-2024 7:00 AM CST - Business Wire Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunomes management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the companys website at ww
5-Nov-2024 7:00 AM CST - Business Wire Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheims Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section o
12-May-2025 3:05 PM CST - Business Wire Immunome Reports First Quarter 2025 Financial Results and Provides Business Update Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update. Immunome continued to build momentum in the first quarter of 2025, said Clay B. Siegall, Ph.D., President and Chief Executive Officer. We remain on track to share topline data for the RINGSIDE trial of varegacestat in the s
4-Apr-2025 7:00 AM CST - Business Wire Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the companys website at ww
19-Mar-2025 3:05 PM CST - Business Wire Immunome Reports Full Year 2024 Financial Results and Provides Business Update Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update. Immunomes efficient execution in 2024 laid the foundation for a productive 2025, said Clay B. Siegall, Ph.D., President and Chief Executive Officer. We are pleased with the progress of our pipeline and, with multiple
25-Feb-2025 7:00 AM CST - Business Wire Immunome to Present at Upcoming March Conferences Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences in March 2025: TD Cowen 45th Annual Health Care Conference Conference Dates: March 3-5, 2025 Presentation Date/Time: March 4, 2025, 1:10 p.m. ET Leerink Partners Global Healthcare Conference 2025 Conference Dates: March 10-12, 2025 Presentation Date/
13-Jan-2025 7:00 AM CST - Business Wire Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 9:45 a.m. PT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the companys website at www.
27-Nov-2024 7:00 AM CST - Business Wire Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunomes management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the companys website at ww
5-Nov-2024 7:00 AM CST - Business Wire Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheims Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section o
